Stay up to date with how Helio is transforming the paradigm of early cancer detection.
Be in the loop
Stay on top of the latest Helio happenings and see our latest press releases
HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available
Helio Genomics and its commercial partner, Fulgent Genetics, Inc. (NASDAQ: FLGT), today announced the commercial launch of HelioLiver™, a multi-analyte blood test that incorporates...
Helio Genomics and Fulgent Genetics to Present New Data on HelioLiver in Late-Breaking Presentation at The Liver Meeting® 2021c
IRVINE, Calif. and TEMPLE CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Helio Genomics, an AI-driven healthcare company developing blood-based early cancer detection tests, and Fulgent Genetics, Inc. (NASDAQ: FLGT)...
Helio Genomics and National Cancer Center Awarded Grant from Ministry of Science and Technology to Evaluate HelioLiver Test in Real-World Screening Scenario in China
Strategic partnership with NCC enables accelerated development of its HelioLiver Test for early liver cancer detection and screening
Helio Genomics Announces China NMPA Acceptance of Registration Application for HelioLiver Test
Liver cancer is the fastest growing and second deadliest cancer worldwide In China alone, more than 400,000 liver cancer diagnoses per year and nearly 100 million people living with hepatitis B virus.
Helio Genomics to Participate in the 41st Annual Cowen Healthcare Conference
Helio Genomics, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced its participation in the 41st Annual Cowen Healthcare Conference.
Positive Data Presented on Helio Genomics Liver Test for the Detection of Hepatocellular Carcinoma (HCC) Advances Product Development
New data demonstrate high accuracy of blood-based cfDNA methylation test for the detection of HCC. Test has potential to outperform current screening modalities for early stage HCC within high risk populations.
Helio Genomics Appoints Wei Li, Ph.D., Leading Expert in Large-Scale Genomics and Bioinformatics, as Key Scientific Advisor
Endowed Chair and Professor of Bioinformatics for the Department of Biological Chemistry at the University of California, Irvine's School of Medicine to Expand AI Expertise.
Laboratory for Advanced Medicine Announces New China CEO Position to Commercialize its Early Cancer Diagnostic for Liver and Colon Cancer Detection in Asia
Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of prominent business leader and...
Laboratory for Advanced Medicine Appoints Former Ancestry Executive as Chief Operations Officer
Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Benjamin Oyler as Chief Operating Officer.
Laboratory For Advanced Medicine Appoints Aarif Nakhooda as Chief Financial Officer
Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Aarif Nakhooda as Chief Financial Officer. Mr. Nakhooda has more than 25 years...
Laboratory For Advanced Medicine Adds High-Profile Cigna Health Senior Executive To Its Board of Directors
IRVINE, Calif., Dec. 3, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection test from a simple blood draw, today announced the appointment of Christopher DeRosa, MBA...
Laboratory for Advanced Medicine Presents New Liver Cancer Test Data at The Liver Meeting 2019
IRVINE, Calif., Nov. 12, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that it will be presenting new data supporting its methylation-based...
Laboratory for Advanced Medicine Appoints Kenneth Chahine, Ph.D., J.D., as Chief Executive Officer
Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Kenneth Chahine, Ph.D., J.D., as Chief Executive Officer and board member...
Laboratory for Advanced Medicine Appoints to its Board of Directors Dr. Alan List, President and CEO, Moffitt Cancer Centerc
IRVINE, Calif., Oct. 23, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Alan List, M.D...
Laboratory for Advanced Medicine Receives FDA Breakthrough Device Designation for Liquid Biopsy Liver Cancer Detection Test
Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company with innovative technologies for the early diagnosis of cancer, today announced that its Liver Cancer detection test has been granted Breakthrough Device...
Laboratory for Advanced Medicine Strengthens Hepatology Board with Addition of Three Distinguished Medical Doctors
Dr. Abou-Alfa, oncologist at Memorial Sloan Kettering; Dr. Gish, Medical Director of Hepatitis B Foundation; and Dr. Hoshida, Director of Translational Research in Liver Cancer at the University of Texas Southwestern Medical Center...
LAM's IvyGene Liquid Biopsy Platform Demonstrates High Diagnostic Capabilities In New Cancer Indication
Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced positive results from a new study that evaluated DNA...
LAM Announces New Data Demonstrating High Diagnostic Potential Of Cell-Free DNA Methylation Assay For Early, Non-Invasive Detection Of Liver, Breast And Colorectal Cancers At AACR 2019
IRVINE, Calif., March 31, 2019 -- Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data...
LAM to Present Data for Cell-Free DNA Methylation Assay for Non-Invasive Diagnosis of Liver, Breast and Colorectal Cancers at AACR Annual Meeting 2019
IRVINE, Calif., Mar. 20, 2019 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers...
Laboratory for Advanced Medicine Announces New Data Demonstrating High Diagnostic Potential of DNA Methylation-Based Biomarkers for Early and Noninvasive Diagnosis of Breast Cancer at San Antonio Breast Cancer Symposium
IRVINE, Calif., Dec. 7, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis...
LAM to Present Data Demonstrating Efficacy of DNA Methylation as Epigenetic Biomarkers for Non-Invasive Breast Cancer Detection at Upcoming San Antonio Breast Cancer Symposium
IRVINE, Calif., Nov. 20, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers...
LAM Announces New Data Validating High Sensitivity and Specificity of DNA Methylation-Based Biomarkers for Noninvasive Diagnosis of Liver Cancer at SITC Meeting
IRVINE, Calif., Nov. 6, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers...
LAM Announces Presentation of DNA Methylation-Based Biomarker Data for Noninvasive Diagnosis of Hepatocellular Carcinoma at SITC 2018
IRVINE, Calif., Oct. 23, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers...c
Laboratory for Advanced Medicine Appoints Jinjie Hu as Chief Regulatory Officer
IRVINE, Calif., July 12, 2018 /PRNewswire/ -- Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company focused on developing innovative technologies for the early diagnosis and intervention of cancers...
Laboratory for Advanced Medicine to Present at 2018 BIO International Convention
IRVINE, Calif., June 4, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, today announced that Justin Li...
Laboratory for Advanced Medicine Commercializes Non-Invasive, Artificial Intelligence-Based IvyGene Blood Test for Cancer Detection
IRVINE, Calif., May 30, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis...
Firefighters Against Cancer and Exposures (FACES) Non-Profit Launches in Texas
IRVINE, Calif., March 14, 2018 — In an effort to help firefighters cover the high cost of cancer treatment as a result of the occupational risk of experiencing higher rates of certain types of cancer than the general U.S. population, Laboratory for Advanced Medicine (LAM) today announced the launch of…
